0
Slide Presentations: Sunday, October 31, 2010 |

Safety and Tolerability of a Budesonide/Formoterol (BUD/FM) Pressurized Metered-Dose Inhaler (pMDI) in Black Adolescents and Adults With Moderate to Severe Persistent Asthma FREE TO VIEW

Sheldon L. Spector, MD; Christopher D. O’ Brien, MD; Tom Uryniak, MS; Ubaldo J. Martin, MD
Author and Funding Information

California Allergy & Asthma Medical Group, Los Angeles, CA



Chest. 2010;138(4_MeetingAbstracts):705A. doi:10.1378/chest.10079
Text Size: A A A
Published online

Abstract

PURPOSE: Concerns exist that black patients with asthma may have a poor response to long-acting β2-adrenergic agonists (Chest. 2006;129:15-26). The safety of BUD/FM pMDI compared with BUD was assessed in black patients with moderate to severe persistent asthma.

METHODS: This 12-week, randomized, double-blind, phase IV study (NCT00702325) included 311 black (self-reported) patients aged ≥12 years with moderate to severe persistent asthma previously receiving medium- to high-dose ICS. Patients symptomatic after 2 weeks on BUD dry powder inhaler (DPI) 90μg ×2 inhalations twice daily (bid) were randomized to BUD/FM pMDI 160/4.5μg ×2 inhalations bid or BUD DPI 180μg ×2 inhalations bid.

RESULTS: Mean treatment exposure (days) was slightly longer for BUD/FM (72.8) versus BUD (67.4). AEs occurred in 63 (41.2%) and 47 (30.3%) patients in the BUD/FM and BUD groups, respectively. Most AEs were mild to moderate in intensity. The most common AEs (≥3% total) were headache (6.5% and 5.2%, respectively), nasopharyngitis (5.2% and 2.6%), and upper respiratory infection (2.6% and 3.9%). Three discontinuations due to AEs occurred: BUD/FM (2: dyspnea, foot fracture), BUD (1: asthma). Three serious AEs were reported during randomized treatment: BUD/FM (1: ruptured ovarian cyst), BUD (2: pyrexia, asthma exacerbation); none was considered treatment-related. The incidence of AEs judged treatment-related by the investigator was low (BUD/FM, 1.3%; BUD, 0.6%). Small, but statistically significant (P≤.013), differences in changes from baseline to end of treatment in sitting systolic and diastolic blood pressure were seen for BUD/FM (1.7 and 0.2 mmHg, respectively) versus BUD (-1.2 and -1.4 mmHg), but these changes remained within normal ranges. No meaningful differences were observed between treatment groups in pulse rate.

CONCLUSION: In this population of black patients with moderate to severe persistent asthma, the safety profile of BUD/FM pMDI was similar to that of BUD DPI and consistent with that observed in previous studies of BUD/FM.

CLINICAL IMPLICATIONS: Findings were consistent with those seen in the general population, supporting use of BUD/FM pMDI in black patients with asthma not controlled on ICS alone.

DISCLOSURE: Sheldon Spector, Grant monies (from industry related sources) This study was funded by AstraZeneca LP. Sheldon L. Spector has received research grants from AstraZeneca, Genentech, Novartis, Schering-Plough, Sepracor, GSK, Boehringer Ingelheim, Amgen.; Shareholder Sheldon L. Spector is a shareholder of Novartis and GSK stocks. Ubaldo J. Martin, Tom Uryniak, and Christopher D. O’ Brien are shareholders of AstraZeneca stocks.; Employee Ubaldo J. Martin, Tom Uryniak, and Christopher D. O’ Brien are employees of AstraZeneca.; Consultant fee, speaker bureau, advisory committee, etc. Sheldon L. Spector is on the Advisory Board of Alcon, AstraZeneca, Schering-Plough and is a speaker for Alcon, AstraZeneca, Genentech, Novartis, Schering-Plough, Merck.; Other Sheldon L. Spector has received honoraria from Alcon, Genentech, Novartis, Schering-Plough, Merck.; No Product/Research Disclosure Information

09:45 AM - 11:00 AM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Guidelines
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543